The mutation status of ADAM17 in pan-cancer cells is shown in Figure 5A. In HCC, ADAM17 has a relatively high mutation rate, with approximately 3% of patients harbouring genetic alterations (Figure 5A,C). This evidence concerns the gene ADAM17 and hepatocellular carcinoma.